Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apellis Pharmaceuticals, Inc.

http://www.apellis.com/

Latest From Apellis Pharmaceuticals, Inc.

Two Avian Flu Vaccines Among 10 New Products To Get EMA Nod

The European Medicines Agency has OKd two new H5N1 jabs, including a pandemic preparedness vaccine intended for use only if a flu pandemic is declared. Eight other products are also heading for EU-wide approval.

Europe Approvals

Crovalimab Gets First Nod In China For PNH, Fiercer Global Competition Awaits

The anti-C5 inhibitor sets an example of swift global trial and approval in China while fiercer competition awaits in the US, Europe and Japan.

China Approvals

The Biggest Drug Launches Expected In 2024

A rundown of the ten most valuable drug launches expected in 2024 from both big pharma and some first-to-market companies. 

Launches Companies

EMA Turns Down Minoryx’s Orphan Drug Nezglyal & Apellis’ Syfovre, OKs Three Others

The European Medicines Agency has recommended against the pan-EU marketing approval of two new medicines, while three others received positive opinions on marketing authorization.

BioPharmaceutical Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register